Several issues worthy of reference and discussion of 2019 edition of the European Association for the Study of the Liver guideline for drug-induced liver injury
10.3760/cma.j.issn.1007-3418.2019.11.018
- VernacularTitle: 欧洲肝病学会2019版药物性肝损伤指南值得借鉴和讨论的若干问题
- Author:
Rongtao LAI
1
;
Chengwei CHEN
2
;
Yuecheng YU
3
Author Information
1. Department of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China
2. Shanghai Liver Diseases Research Center, 905 Hospital, Nanjing Military Command, Shanghai 200235, China
3. Liver Diseases Center of PLA, General Hospital of Eastern Theater Command, and Bayi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing 210002, China
- Publication Type:Review
- Keywords:
Drug induced liver injury;
European association for the study of the liver;
Clinical practice guidelines;
Discussion
- From:
Chinese Journal of Hepatology
2019;27(11):910-912
- CountryChina
- Language:Chinese
-
Abstract:
The 2019 European Association for the Study of the Liver (EASL) Clinical Practice Guidelines (hereinafter referred to as the EASL Guidelines) extracted the required evidence from detailed research materials, and rigorously graded and condensed the varying strengths of evidence into 32 recommendations and 14 statements (recommendations and reminders) for drug-induced Liver Injury (DILI). This guideline has important reference values for helping clinicians to further improve their understanding of DILI and the level of clinical diagnosis, treatment and prevention; however, there are still several issues worthy of further discussion.
